# Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

> **NCT06795412** · PHASE1,PHASE2 · RECRUITING · sponsor: **Pyxis Oncology, Inc** · enrollment: 220 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** PYX-201
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT06795412
- **Lead sponsor:** Pyxis Oncology, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2027-12-06
- **Final completion:** 2027-12-06
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06795412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06795412, "Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06795412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*